Evidence map›Paper›PMID 38523846›Full record

ArticleTherapeutic advances in medical oncology2024

Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.

Su-Jin Choi, Jii Bum Lee, Jae Hwan Kim, Min Hee Hong, Byoung Chul Cho, Sun Min Lim

Abstract read
In one paragraph

Article in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Su-Jin ChoiSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Jii Bum LeeDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.ORCID https://orcid.org/0000-0001-5608-3157
Jae Hwan KimSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Min Hee HongDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Byoung Chul ChoDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.ORCID https://orcid.org/0000-0002-5562-270X
Sun Min LimDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, South Korea.ORCID https://orcid.org/0000-0001-7694-1593

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Identifying actionable driver mutations Methods: All surgically resected NSCLC samples ( Results: Stage distribution post-surgery was 80% I ( Conclusion: TSO500 and F1CDx showed robust analytical performance for TMB assessment with TSO500 showing stronger concordance of TMB with high PD-L1 expression. As the paradigm for the management of early-resected NSCLC continues to evolve, understanding TMB and the mutation landscape may help advance clinical outcomes for this subset of patients.

Indexed as

comprehensive genomic profilingearly stagenon-small-cell lung cancerPD-L1tumor mutation burden

Identifiers

PMID38523846
PMCPMC10958800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.